76 results on '"Skowasch, Dirk"'
Search Results
2. Exploring pulmonary involvement in newly diagnosed rheumatoid arthritis, and psoriatic arthritis: a single center study.
- Author
-
Schäfer, Valentin Sebastian, Winter, Lone, Skowasch, Dirk, Bauer, Claus-Jürgen, Pizarro, Carmen, Weber, Marcel, Kütting, Daniel, Behning, Charlotte, Brossart, Peter, and Petzinna, Simon Michael
- Subjects
- *
PULMONARY function tests , *RHEUMATOID factor , *MEDICAL screening , *ARTHRITIS , *PATHOLOGICAL laboratories - Abstract
Objectives: This cross-sectional study aimed to determine the prevalence, manifestation, and risk factors of pulmonary involvement in newly diagnosed, untreated rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients, and to evaluate the efficacy of various diagnostic tools in screening for pulmonary involvement. Methods: Untreated, newly diagnosed patients with RA and PsA underwent an extensive multimodal diagnostic approach including clinical and laboratory assessment, pulmonary function tests, and chest radiography. Results: We recruited 50 arthritis patients (26 RA, 24 PsA) and 26 control subjects. Respiratory symptoms were found in 36.0 % of arthritis patients and 11.5 % of controls (p = 0.031). Pathologically reduced breathing width (< 3.0 cm) was significantly more common in arthritis patients (64.0 %) than in controls (23.1 %) (p < 0.001). Pulmonary function test results did not differ significantly between groups. Chest radiography revealed pulmonary involvement in 37.0 % of arthritis patients, higher in RA (50.0 %) than in PsA (22.7 %). Notably, only 35.3 % of arthritis patients with radiographic pulmonary involvement were symptomatic, with 64.7 % being asymptomatic. Radiographic pulmonary involvement was associated with advanced age (p = 0.002) and increased rheumatoid factor levels (p = 0.024). Conclusion: Our research underscores the significant prevalence of largely asymptomatic pulmonary involvement in newly diagnosed RA and PsA patients. These findings highlight the importance of an early, multidisciplinary screening approach, particularly for high-risk individuals. Further large-scale studies are needed to develop comprehensive screening protocols to improve early detection and treatment of pulmonary involvement in arthritis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Endoscopic Lung Volume Reduction in COPD: The Impact of Coil Implantation on Patients' Physical Activity.
- Author
-
Biener, Leonie, Skowasch, Dirk, Hollmann, Sophia, Schreiber, Tina, Nickenig, Georg, Fimmers, Rolf, and Pizarro, Carmen
- Subjects
- *
PULMONARY emphysema treatment , *ACADEMIC medical centers , *ACCELEROMETERS , *ENDOSCOPY , *ENERGY metabolism , *LONGITUDINAL method , *OBSTRUCTIVE lung diseases , *PNEUMONECTOMY , *QUALITY of life , *PHYSICAL activity - Abstract
Endoscopic lung volume reduction (ELVR) is an emerging therapy option for the treatment of severe emphysema in COPD. To which extent patients profit from lung volume reduction via coils (LVRC) regarding morbidity, mortality, and quality of life is not clear yet. In this monocentric prospective cohort study, 13 COPD patients with severe emphysema (residual volume [RV] >225%) were enrolled at the University Hospital of Bonn. Activity measurements were assessed by a validated accelerometer wristband. By LVRC, RV could be reduced by 0.13 L to 5.54 ± 1.29 L. We could show a clinically relevant improvement in patients' physical activity after LVRC, measured as daily step count (497.7 ± 72.6 vs. 1,913.7 ± 182.7 steps/day, p = 0.03) and mean daily active energy expenditure (714.4 ± 73.6 vs. 2,321.3 ± 163.9 joules, p = 0.03). This improvement in physical activity is possibly associated with a positive effect on patients' morbidity and mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
4. Assessing sleep-related breathing disorders among newly diagnosed rheumatoid and psoriatic arthritis patients: a cross-sectional study.
- Author
-
Petzinna, Simon M., Winter, Lone, Skowasch, Dirk, Pizarro, Carmen, Weber, Marcel, Kütting, Daniel, Behning, Charlotte, Bauer, Claus-Jürgen, and Schäfer, Valentin S.
- Subjects
- *
PSORIATIC arthritis , *RHEUMATOID arthritis , *SLEEP apnea syndromes , *EPWORTH Sleepiness Scale , *CROSS-sectional method , *RESPIRATION , *MEDICAL screening - Abstract
Objectives: This cross-sectional study aimed to determine the prevalence and risk factors for sleep-related breathing disorders (SRBD) in newly diagnosed, untreated rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients, and to develop a screening algorithm for early detection. Methods: We evaluated newly diagnosed RA or PsA patients using the Epworth Sleepiness Scale (ESS) questionnaire, cardiorespiratory polygraphy (RPG), and clinical and laboratory assessments. Sleep apnea syndrome (SAS) was diagnosed based on pathological RPG findings excessive daytime sleepiness, defined as ESS score above 10. Results: The study included 39 patients (22 RA, 17 PsA) and 23 controls. In RPG, SRBD was identified in 38.5% of arthritis patients compared to 39.1% of controls (p = 1.00), with male gender (p =.004) and age (p <.001) identified as risk factors. Excessive daytime sleepiness was noted in 36.4% of RA patients, 17.6% of PsA patients, and 21.7% of controls. Of the 24 patients diagnosed with SRBD, 41.6% met the criteria for SAS. SAS prevalence was 31.8% among RA patients, 0% in PsA patients, and 13% in controls. A significant association was observed between excessive daytime sleepiness and SRBD (p =.036). Conclusion: Our findings reveal a high prevalence of SRBD in newly diagnosed, untreated RA and PsA patients in ESS and RPG, with excessive daytime sleepiness being a reliable predictor of SRBD. Patients with RA exhibited a higher predisposition to SAS. We therefore suggest incorporating ESS and RPG as screening tools in RA or PsA for early detection and management of SRBD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Management of sudden cardiac death in cardiac sarcoidosis using the wearable cardioverter defibrillator.
- Author
-
Skowasch, Dirk, Ringquist, Steven, Nickenig, Georg, and Andrié, René
- Subjects
- *
CARDIAC patients , *SARCOIDOSIS treatment , *VENTRICULAR fibrillation treatment , *DEFIBRILLATORS , *CLINICAL trials - Abstract
Background: Patients with cardiac sarcoidosis are at increased risk of ventricular tachycardia/fibrillation. Objective: We tested the hypothesis that the wearable cardioverter defibrillator can be used to mitigate the risk of sudden cardiac death among cardiac sarcoidosis patients. Methods: A retrospective review of the commercial database identified cardiac sarcoidosis patients who wore the wearable cardioverter defibrillator. Evidence for cardiac sarcoidosis diagnosis as well as demographic, co-morbidity and left ventricular ejection fraction were provided by patient clinical records. Clinical data also included daily wearable cardioverter defibrillator wear, shock treatment and survival information. Results: The wearable cardioverter defibrillator was worn by 46 cardiac sarcoidosis patients, 24 (52%) male. The median age was 48 years and median left ventricular ejection fraction was 30%. The wearable cardioverter defibrillator was worn a median of 23.6 hours each day. There were 11 ventricular tachycardia/fibrillation episodes occurring in 10 (22%) patients. Ventricular tachycardia/fibrillation occurred over a range of 1 to 79 days, median 24 days. First-shock success for conversion of ventricular tachycardia/fibrillation was 100%. Patient survival 24 hours after shock treatment was 100%. Follow up to determine the reason for discontinuing wearable cardioverter defibrillator use indicated that among shocked patients 7 received an implantable cardioverter defibrillator, 1 patient was admitted to the hospital ending in death 2 weeks after discontinuing wearable cardioverter defibrillator use, and 2 patients were lost to follow up. Among the not shocked patients, there were 16 who received an implantable cardioverter defibrillator while 7 achieved improved left ventricular ejection fraction. Conclusion: Management of sudden cardiac death among cardiac sarcoidosis patients was aided by the wearable cardioverter defibrillator resulting in successful termination of ventricular tachycardia/fibrillation upon delivery of shock. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
6. Asthma is associated with atherosclerotic artery changes.
- Author
-
Tuleta, Izabela, Skowasch, Dirk, Aurich, Florian, Eckstein, Nicolas, Schueler, Robert, Pizarro, Carmen, Schahab, Nadjib, Nickenig, Georg, Schaefer, Christian, and Pingel, Simon
- Subjects
- *
ASTHMA , *INFLAMMATION , *ANKLE brachial index , *ATHEROSCLEROTIC plaque , *IMMUNOGLOBULIN E - Abstract
Asthma is a chronic airway inflammation with a potential systemic impact. Atherosclerosis is a chronic inflammatory artery disease. The aim of our study was to prove if there is a correlation between the occurrence of asthma and increased atherosclerotic vessel disorders. Vessel status was compared between mild-to-moderate, severe allergic asthma and matched controls. Measurements of artery stiffness were calculated by central pulse wave velocity, ultrasonographic strain imaging and ankle-brachial index. Atherosclerotic plaque burden was assessed by colour-coded duplex sonography. Additionally, analysis of cardiovascular and asthma blood markers was conducted. Arterial stiffness expressed as an increased central pulse wave velocity and decreased circumferential and radial strains as well as the prevalence of media sclerosis were significantly higher among asthma patients compared to controls. Atherosclerotic plaque burden was relevantly increased in asthma groups vs. controls (severe asthma: 43.1%, mild-to-moderate asthma: 25.0%, control: 14.3% of study participants). Except for the elevated IgE and fibrinogen concentrations as well as leukocyte number there were no relevant differences in the blood parameters between the groups. Allergic asthma is associated with distinct atherosclerotic artery changes compared to the respectively matched control collective. The severity of asthma correlates with more pronounced pathological vessel alternations. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
7. A Long-Term Follow-Up Investigation of Endobronchial Valves in Emphysema (the LIVE Study): Study Protocol and Six-Month Interim Analysis Results of a Prospective Five-Year Observational Study.
- Author
-
Skowasch, Dirk, Fertl, andreas, Schwick, Björn, Schäfer, Harald, Hellmann, andreas, and Herth, Felix J.F.
- Subjects
- *
PULMONARY emphysema , *ENDOSCOPY , *LONGITUDINAL method , *MEDICAL cooperation , *PNEUMONECTOMY , *RESEARCH , *TREATMENT effectiveness , *VITAL capacity (Respiration) , *DESCRIPTIVE statistics - Abstract
Background: Randomized controlled trials indicate that significant lung volume reduction (ELVR) can be obtained with Zephyr® valves by occluding the target lobe in the absence of collateral ventilation, leading to relevant functional benefits in advanced emphysema patients. Objectives: To observe the long-term effects of endobronchial valve (EBV) implantation in emphysema patients screened by Chartis assessment in the context of daily pulmonology practice. Methods: The LIVE Study is a prospective, observational, open-label, single-arm, multicenter trial conducted in Germany. 498 patients included in this interim analysis were enrolled between July 2, 2012, and September 16, 2014. The 6-month follow-up visit data were recorded for 343 patients (safety population), and complete data sets were available for 321 treated patients (efficacy population) - 56.4% male, age: 64.5 years, forced expiratory volume in 1 s (FEV1 ) % predicted: 31.3%, residual volume (RV) % predicted: 252%. Results: Efficacy results at 6 months: FEV1 (l) increased by +100 ml (+11.9%), RV (l) decreased by -0.42 liter, and the COPD Assessment Test score decreased by -3.14 points (each p < 0.0001). Safety outcomes: A total of 66 adverse events (AEs; with 50 serious AEs - SAEs) were reported in 55 patients (16%) during the hospital stay for EBV placement - pneumothorax (35 cases), chronic obstructive pulmonary disease (COPD) exacerbation (5 cases), and pneumonia (4 cases). During the subsequent 6-month follow-up window, 170 SAEs were recorded in 125 patients (36.4%), predominantly COPD exacerbation (53% of the SAEs). Conclusion: The current results of this large-scale German observational study performed in the context of daily practice further demonstrates that ELVR with Zephyr® valves is an effective and well-tolerated treatment option in advanced emphysema. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
8. Influence of Smoking Dosage and Chronic Obstructive Lung Disease on the Incidence of Appropriate Therapies and Mortality in Patients with Structural Heart Disease and an Implantable Cardioverter Defibrillator.
- Author
-
KREUZ, JENS, SKOWASCH, DIRK, KAMRATH, PHILIP, LORENZEN, HENNING, TIYERILI, VEDAT, LINHART, MARKUS, NICKENIG, GEORG, and SCHWAB, JÖRG O.
- Subjects
- *
CONFIDENCE intervals , *DOSE-response relationship in biochemistry , *HEART diseases , *IMPLANTABLE cardioverter-defibrillators , *LONGITUDINAL method , *OBSTRUCTIVE lung diseases , *MORTALITY , *NICOTINE , *PLETHYSMOGRAPHY , *RISK assessment , *SMOKING , *SPIROMETRY , *RETROSPECTIVE studies , *DESCRIPTIVE statistics , *KAPLAN-Meier estimator - Abstract
Background Smoking is known as a relevant risk factor for severe cardiac morbidities and mortality. This study was initiated to explore the influence of smoking dosage and presence of chronic obstructive lung disease (COPD) on the incidence of appropriate implantable cardioverter defibrillator (ICD) interventions and on mortality. Methods Prior studies on patients equipped with an ICD suggested that nicotine consumption increases the risk of experiencing an appropriate ICD therapy. There is no substantial data regarding the influence of cigarette smoking dosage on overall mortality in such endangered patients. A total of 349 patients with structural heart disease, either coronary artery disease or nonischemic cardiomyopathy equipped with an ICD, were included. Every patient answered a questionnaire regarding his smoking status and performed a spirometry and body plethysmography. Results A total of 104 patients (30%) suffered from COPD. Fifty-eight patients (17%) were 'current smokers,' 196 patients (56%) were revealed as 'former smokers,' while 93 (27%) patients were registered as 'never smokers.' A total of 163 patients (47%) received at least one appropriate ICD intervention during follow-up (median 48 ± 8 months). Twenty-three patients died during this study (6.6%). There was no association of COPD with the incidence of appropriate ICD therapies or mortality. Smoking dosage revealed as a significant risk factor for both appropriate ICD interventions (hazard ratio [HR] 1.5 for 60 pack years [PY] P = 0.04) and mortality (HR 2.3 for 60 PY P = 0.02). Conclusion This study demonstrates a dose-related increased risk of smokers for appropriate ICD interventions and mortality. The results of this trail urge a strict nicotine abstinence, especially in patients with a structural heart disease undergoing ICD therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
9. Usefulness of Sleep-Disordered Breathing to Predict Occurrence of Appropriate and Inappropriate Implantable-Cardioverter Defibrillator Therapy in Patients With Implantable Cardioverter-Defibrillator for Primary Prevention of Sudden Cardiac Death.
- Author
-
Kreuz, Jens, Skowasch, Dirk, Horlbeck, Fritz, Atzinger, Carolin, Schrickel, Jan W., Lorenzen, Henning, Nickenig, Georg, and Schwab, Jörg O.
- Subjects
- *
HEART failure , *SLEEP disorders , *IMPLANTABLE cardioverter-defibrillators , *VENTRICULAR arrhythmia - Abstract
Advanced heart failure (HF) is associated with severe sleep-disordered breathing (SDB). In addition, most patients with HF are treated with an implantable cardioverter-defibrillator (ICD) for primary prevention of sudden cardiac death. The incidence of ICD therapy in such a patient cohort with SDB has never been investigated. The present study sought to determine the effect of SDB on the incidence of appropriate and inappropriate ICD therapy in patients with a categorical primary prevention ICD indication. A total of 133 consecutive ICD patients with New York Heart Association class II-III HF and depressed left ventricular function (S35%) with no history of ventricular arrhythmia underwent a sleep study before ICD implantation and were followed for 24 ± 8 months, prospectively. A relevant SDB was defined as an apnea-hypopnea index of ≽10 events/hour. Of these 133 patients, 82 (62%) had SDB. Overweight (body mass index >29.1 vs 24.7 kg/m²; p <0.001) was identified as the only independent risk factor for SDB. Appropriate ICD therapy intervention was significantly greater among patients with SDB than among patients without SDB (54% vs 34%, p = 0.03). Inappropriate ICD therapy intervention was documented more often in patients with SDB (n = 24 [29%] vs 7 [14%]; p = 0.04). An apnea-hypopnea index >10 events/hour was an independent predictor of appropriate ICD therapy on multivariate analysis (odds ratio 2.5, 95% confidence interval 1.8 to 4.04; p = 0.01). In conclusion, the present study is the first trial exploring the effect of SDB on the incidence of appropriate and inappropriate ICD therapy in patients with HF with a primary prevention indication. These results indicate that a preimplantation sleep study will identify patients with HF prone to receive appropriate and inappropriate ICD therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
10. Cells of Primarily Extravascular Origin in Neointima Formation following Stent Implantation.
- Author
-
Tuleta, Izabela, Skowasch, Dirk, Peuster, Matthias, Nickenig, Georg, and Bauriedel, Gerhard
- Subjects
- *
CORONARY restenosis , *SURGICAL stents , *TRANSLUMINAL angioplasty , *IMMUNOHISTOCHEMISTRY techniques , *NEOVASCULARIZATION inhibitors , *SCIENTIFIC method - Abstract
Objectives: In-stent restenosis due to neointima formation is a major limitation following stent implantation. Recently, several studies reported mobilization of primarily extravascular cells to the arterial sites after balloon angioplasty. Therefore, the goal of the present study was to assess the coordinated neointimal expression of endothelial progenitor, dendritic and neural crest-derived cells after stent implantation. Methods: Male minipigs underwent stent implantation in abdominal aortic segments. Animals were sacrificed at 1, 7, 14, 30, 60 or 90 days. Cross sections of the injured vessels were obtained for immunohistochemistry using specific antibodies for the detection of endothelial progenitor (CD133), dendritic (S100) and neural crest-derived cells (GFAP), as well as monocytes/macrophages (CD14) and T lymphocytes (CD3). Results: As a key finding, frequency of CD133, S100, GFAP, CD14 and CD3 (18.5 ± 3.6, 14.9 ± 1.8, 10.6 ± 1.1, 40.2 ± 8.3 and 5.0 ± 0.6%, respectively) in neointima was maximal at day 7. With ongoing neointima enlargement, expression of these cells decreased. In advanced neointima, labeled cells were predominantly localized at luminal and stented sites. Media showed almost no immunoreactivity of the markers studied, whereas adventitial zones of neovascularization revealed some signals. Conclusions: Endothelial progenitor, dendritic, neural crest-derived and inflammatory cells are consistently recruited into arterial neointima, mostly at early time points after stent implantation. Copyright © 2007 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
11. Pathogen Burden, Inflammation, Proliferation and Apoptosis in Human In-Stent Restenosis.
- Author
-
Skowasch, Dirk, Jabs, Alexander, Andrié, René, Dinkelbach, Sabine, Schiele, Thomas M., Wernert, Nicolas, Lüderitz, Berndt, and Bauriedel, Gerhard
- Subjects
- *
CORONARY restenosis , *INFLAMMATION , *APOPTOSIS , *CELL death , *PATHOGENIC microorganisms , *SURGICAL stents - Abstract
Pathogenic events leading to in-stent restenosis (ISR) are still incompletely understood. Among others, inflammation, immune reactions, deregulated cell death and growth have been suggested. Therefore, atherectomy probes from 21 patients with symptomatic ISR were analyzed by immunohistochemistry for pathogen burden and compared to primary target lesions from 20 stable angina patients. While cytomegalovirus, herpes simplex virus, Epstein-Barr virus and Helicobacter pylori were not found in ISR, acute and/or persistent chlamydial infection were present in 6/21 of these lesions (29%). Expression of human heat shock protein 60 was found in 8/21 of probes (38%). Indicated by distinct signals of CD68, CD40 and CRP, inflammation was present in 5/21 (24%), 3/21 (14%) and 2/21 (10%) of ISR cases. Cell density of ISR was significantly higher than that of primary lesions (977 ± 315 vs. 431 ± 148 cells/mm2; p < 0.001). There was no replicating cell as shown by Ki67 or PCNA. TUNEL+ cells indicating apoptosis were seen in 6/21 of ISR specimens (29%). Quantitative analysis revealed lower expression levels for each intimal determinant in ISR compared to primary atheroma (all p < 0.05). In summary, human ISR at the time of clinical presentation is characterized by low frequency of pathogen burden and inflammation, but pronounced hypercellularity, low apoptosis and absence of proliferation. Copyright © 2004 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
12. Presence of bone-marrow- and neural-crest-derived cells in intimal hyperplasia at the time of clinical in-stent restenosis
- Author
-
Skowasch, Dirk, Jabs, Alexander, Andrié, René, Dinkelbach, Sabine, Lüderitz, Berndt, and Bauriedel, Gerhard
- Subjects
- *
PRECANCEROUS conditions , *SURGICAL stents , *BONE marrow , *CELLS - Abstract
Objective: Intralesional data of coronary target lesions following stent implantation are infrequent. In addition, there is ongoing controversy on the origin of neointimal cells. In this respect, several lines of evidence revealed bone-marrow-derived endothelial progenitor and dendritic cells (DCs) as well as neural-crest-derived cells (NCCs) to contribute to atherosclerosis. Therefore, the objective of the present study was to assess cellularity, cell type and origin of neointimal cells in in-stent restenosis (ISR). Methods: Atherectomy specimens from 17 patients with coronary in-stent restenosis (n=10; time post-stenting 5±3 months) and with peripheral in-stent restenosis (n=7; 7±3 months) versus those from 10 patients with primary lesions were immunohistochemically examined for the presence of the determinants CD34, AC133, S100, glial fibrillary acidic protein (GFAP), neuron-specific enolase (NSE), nerve growth factor receptor (NGFR) and α-smooth muscle actin followed by computer-assisted morphometry. Results: In-stent restenosis probes consistently demonstrated homogeneous hypercellularity (942±318 cells/mm2) compared to de novo lesions (347±120 cells/mm2, P<0.001). α-smooth muscle actin positive cells occupied 67% of intimal cells in in-stent restenosis. As a key finding, expression of endothelial progenitor cells (CD34: 7.1±2.5% positive/total cells vs. 0.6±0.7%, P<0.001; AC133: 7.0±3.4% vs. 1.0±0.7%, P<0.001), dendritic cells (S100: 9.8±5.6% vs. 1.4±1.1%, P<0.001) and neural-crest-derived cells (GFAP: 7.9±2.4% vs. 3.1±1.0%; NSE: 4.4±2.6% vs. 1.3±1.6%; NGFR: 4.2±2.5% vs. 1.1±0.7%; each P<0.001) was significantly increased in in-stent restenosis compared to primary lesions. Conclusions: Bone-marrow- and neural-crest-derived cells, the most dendritic cells, are consistently present in in-stent restenosis, whereas α-smooth muscle actin positive cells constitute the largest intimal cell pool. Our data suggest the recruitment of primarily extravascular cells within neointima formation in human in-stent restenosis. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
13. Identification of a novel Comamonas testosteroni gene encoding a steroid-inducible extradiol dioxygenase
- Author
-
Skowasch, Dirk, Möbus, Eric, and Maser, Edmund
- Subjects
- *
GRAM-negative bacteria , *GENE expression , *STEROIDS , *POLYCYCLIC aromatic compounds - Abstract
Comamonas testosteroni is a Gram-negative bacterium that can grow on steroids and polycyclic aromatic hydrocarbons (PAH) as sole carbon and energy source. Complete mineralisation of these compounds is achieved through complex metabolic pathways comprising a set of inducible enzymes. Whereas the degradation pathways for PAHs have been intensively studied, patterns of enzymes leading to ring fissions of the steroid nucleus are unclear. Several intermediates of the steroid and PAH degradation pathways have similar structures therefore the question remains of whether both classes are substrates of different degradation routes or whether some catabolic enzymes function in both pathways. Interestingly, our studies reveal that testosterone simultaneously induces the expression of steroid- and PAH-catabolising enzymes in C. testosteroni. By cloning the gene, one of these testosterone-inducible proteins (TIP1) turned out to be biphenyl-2,3-diol-1,2-dioxygenase. This enzyme has been described to convert 2,3-dihydroxybiphenyl into 2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoic acid in PAH degradation. The gene was found on a cluster encoding TIP1, three orfs, and another testosterone-inducible protein (TIP6) of unknown function. The deduced amino acid sequence of TIP1 revealed that the enzyme contains 299 amino acids (34 kDa) and shares homologies to a variety of other extradiol dioxygenases. Based on the similar catechol moieties in PAH and steroid intermediates, together with its inducibility by testosterone, it is conceivable that TIP1 functions as a steroid extradiol dioxygenase to convert steroidal secocatechols into the disecoandrostanes. Our data suggest a role of the reported TIP1 protein in both the degradation pathways for steroids and aromatic hydrocarbons. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
14. Left Internal Mammary Angiography Complicated by Subclavian Tortuousity: A Technical Note.
- Author
-
Skowasch, Dirk, Lüderitz, Berndt, and Bauriedel, Gerhard
- Subjects
- *
INTERNAL thoracic artery , *CATHETERIZATION , *CORONARY restenosis , *MEDICAL imaging systems , *ANGIOGRAPHY , *CARDIOLOGY - Abstract
Current elective bypass procedures frequently involve placement of a left internal mammary artery (LIMA). Accordingly, there is an increased need to prove either preoperative adequacy or postoperative patency of this graft. We report a patient with a tortuous left subclavian artery inaccessible for any standard catheterization technique for LIMA opacification. The problem was overcome by a CHOICE PT guidewire whose trackability permitted the passage through the subclavian kinking and, subsequently, to coaxially advance a multipurpose catheter to the entrance of the LIMA. The described setting may be helpful for diagnostic LIMA imaging in selected cases. (J Interven Cardiol 2005;18:309–311) [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
15. Primary extragonadal germ cell tumor of the prostate in a young man.
- Author
-
Bastian, Patrick J., Skowasch, Dirk, Bauriedel, Gerhard, Behrens, Peter, Müller, Stefan C., and Albers, Peter
- Subjects
- *
PROSTATE tumors , *TERATOMA , *PROSTATECTOMY , *DRUG therapy , *MYOCARDIAL infarction , *ANGIOGRAPHY - Abstract
We report on a case of malignant prostatic teratoma treated with radical cystoprostatectomy and cisplatin-based chemotherapy because of intraoperative tumor rupture. During chemotherapy the patient suffered acute myocardial infarction and was treated with percutanous coronarangiography and stenting. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
16. German asthma net: Nasal polyposis in patients in the severe asthma registry.
- Author
-
Bal, Christina, Stoshikj, Slagjana, Milger, Katrin, Skowasch, Dirk, Gappa, Monika, Koerner‐Rettberg, Cordula, Jandl, Margret, Schmidt, Olaf, Ehmann, Rainer, Taube, Christian, Hamelmann, Eckard, Buhl, Roland, Korn, Stephanie, and Idzko, Marco
- Published
- 2024
- Full Text
- View/download PDF
17. Disease trajectories in interstitial lung diseases – data from the EXCITING-ILD registry.
- Author
-
Buschulte, Katharina, Kabitz, Hans-Joachim, Hagmeyer, Lars, Hammerl, Peter, Esselmann, Albert, Wiederhold, Conrad, Skowasch, Dirk, Stolpe, Christoph, Joest, Marcus, Veitshans, Stefan, Höffgen, Marc, Maqhuzu, Phillen, Schwarzkopf, Larissa, Hellmann, Andreas, Pfeifer, Michael, Behr, Jürgen, Karpavicius, Rainer, Günther, Andreas, Polke, Markus, and Höger, Philipp
- Subjects
- *
INTERSTITIAL lung diseases , *LUNGS , *PROGRESSION-free survival , *IDIOPATHIC pulmonary fibrosis , *VITAL capacity (Respiration) , *SURVIVAL rate , *SURVIVAL analysis (Biometry) , *MULTIVARIATE analysis - Abstract
Background: Interstitial lung diseases (ILD) comprise a heterogeneous group of mainly chronic lung diseases with different disease trajectories. Progression (PF-ILD) occurs in up to 50% of patients and is associated with increased mortality. Methods: The EXCITING-ILD (Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases) registry was analysed for disease trajectories in different ILD. The course of disease was classified as significant (absolute forced vital capacity FVC decline > 10%) or moderate progression (FVC decline 5–10%), stable disease (FVC decline or increase < 5%) or improvement (FVC increase ≥ 5%) during time in registry. A second definition for PF-ILD included absolute decline in FVC % predicted ≥ 10% within 24 months or ≥ 1 respiratory-related hospitalisation. Risk factors for progression were determined by Cox proportional-hazard models and by logistic regression with forward selection. Kaplan-Meier curves were utilised to estimate survival time and time to progression. Results: Within the EXCITING-ILD registry 28.5% of the patients died (n = 171), mainly due to ILD (n = 71, 41.5%). Median survival time from date of diagnosis on was 15.5 years (range 0.1 to 34.4 years). From 601 included patients, progression was detected in 50.6% of the patients (n = 304) with shortest median time to progression in idiopathic NSIP (iNSIP; median 14.6 months) and idiopathic pulmonary fibrosis (IPF; median 18.9 months). Reasons for the determination as PF-ILD were mainly deterioration in lung function (PFT; 57.8%) and respiratory hospitalisations (40.6%). In multivariate analyses reduced baseline FVC together with age were significant predictors for progression (OR = 1.00, p < 0.001). Higher GAP indices were a significant risk factor for a shorter survival time (GAP stage III vs. I HR = 9.06, p < 0.001). A significant shorter survival time was found in IPF compared to sarcoidosis (HR = 0.04, p < 0.001), CTD-ILD (HR = 0.33, p < 0.001), and HP (HR = 0.30, p < 0.001). Patients with at least one reported ILD exacerbation as a reason for hospitalisation had a median survival time of 7.3 years (range 0.1 to 34.4 years) compared to 19.6 years (range 0.3 to 19.6 years) in patients without exacerbations (HR = 0.39, p < 0.001). Conclusion: Disease progression is common in all ILD and associated with increased mortality. Most important risk factors for progression are impaired baseline forced vital capacity and higher age, as well as acute exacerbations and respiratory hospitalisations for mortality. Early detection of progression remains challenging, further clinical criteria in addition to PFT might be helpful. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Impact of interstitial lung disease on left ventricular myocardial function.
- Author
-
Stumpf, Max Jonathan, Wirtz, Marina Michaela Luise, Fleddermann, Max Fabian, Biener, Leonie, Weinhold, Leonie, Weber, Marcel, Schaefer, Christian Alexander, Nickenig, Georg, Skowasch, Dirk, and Pizarro, Carmen
- Subjects
- *
INTERSTITIAL lung diseases , *SPECKLE tracking echocardiography , *GLOBAL longitudinal strain , *ECHOCARDIOGRAPHY , *LEFT heart ventricle , *VITAL capacity (Respiration) - Abstract
Background: Interstitial lung disease (ILD) comprises a wide variety of pulmonary parenchymal disorders within which progressive fibrosing ILD (PF-ILD) constitutes a phenotypic subset. By use of speckle tracking-based strain analysis we aimed to evaluate the degree of left ventricular (LV) dysfunction in progressive vs. non-progressive fibrosing ILD (non-PF-ILD). Methods: A total of 99 ILD patients (mean age 63.7 ± 13.5 years, 37.4% female), composed of 50 PF-ILD and 49 non-PF-ILD patients, and 33 controls were prospectively enrolled and underwent conventional and speckle tracking echocardiography. Additional laboratory and pulmonary function testing, as well as six-minute walk test were performed. Results: As compared to the non-PF-ILD cohort, PF-ILD patients exhibited a significantly impaired forced vital capacity (2.4 ± 1.0l vs. 3.1 ± 0.9l, p = 0.002), diffusion capacity for carbon monoxide (DLCO, 25.6 ± 16.3% predicted vs. 43.6 ± 16.67% predicted, p <0.001) and exercise capacity response as measured by the six-minute walk test distance (268.1 ± 178.2m vs. 432.6 ± 94.2m, p <0.001). Contrary to conventional echocardiographic LV parameters, both regional and global longitudinal LV strain measurements were significantly altered in ILD patients as compared to controls. No differences in LV strain were found between both patient groups. Significant correlations were observed between global longitudinal strain, on the one hand, and systemic inflammation markers, total lung capacity (TLC) and DLCO, on the other hand (high-sensitivity C-reactive protein: Pearson´s r = -0.30, p< 0.001; interleukin-6: Pearson´s r = -0.26, p = 0.007; TLC % predicted: Pearson´s r = 0.22, p = 0.02; DLCO % predicted: Pearson´s r = 0.21, p = 0.02). Conclusions: ILD is accompanied by LV dysfunction. LV functionality inversely correlates with the severity of the restrictive ventilatory defect and inflammation marker levels. These observations support the assumption of persistent low-grade systemic inflammation that may link systemic cardiovascular function to ILD status. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Hospitalisation patterns in interstitial lung diseases: data from the EXCITING-ILD registry.
- Author
-
Buschulte, Katharina, Kabitz, Hans-Joachim, Hagmeyer, Lars, Hammerl, Peter, Esselmann, Albert, Wiederhold, Conrad, Skowasch, Dirk, Stolpe, Christoph, Joest, Marcus, Veitshans, Stefan, Höffgen, Marc, Maqhuzu, Phillen, Schwarzkopf, Larissa, Hellmann, Andreas, Pfeifer, Michael, Behr, Jürgen, Karpavicius, Rainer, Günther, Andreas, Polke, Markus, and Höger, Philipp
- Subjects
- *
INTERSTITIAL lung diseases , *HOSPITAL care , *CONNECTIVE tissue diseases , *PULMONARY hypertension , *PROGRESSION-free survival - Abstract
Background: Interstitial lung diseases (ILD) comprise a heterogeneous group of mainly chronic lung diseases with more than 200 entities and relevant differences in disease course and prognosis. Little data is available on hospitalisation patterns in ILD. Methods: The EXCITING-ILD (Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases) registry was analysed for hospitalisations. Reasons for hospitalisation were classified as all cause, ILD-related and respiratory hospitalisations, and patients were analysed for frequency of hospitalisations, time to first non-elective hospitalisation, mortality and progression-free survival. Additionally, the risk for hospitalisation according to GAP index and ILD subtype was calculated by Cox proportional-hazard models as well as influencing factors on prediction of hospitalisation by logistic regression with forward selection. Results: In total, 601 patients were included. 1210 hospitalisations were recorded during the 6 months prior to registry inclusion until the last study visit. 800 (66.1%) were ILD-related, 59.3% of admissions were registered in the first year after inclusion. Mortality was associated with all cause, ILD-related and respiratory-related hospitalisation. Risk factors for hospitalisation were advanced disease (GAP Index stages II and III) and CTD (connective tissue disease)-ILDs. All cause hospitalisations were associated with pulmonary hypertension (OR 2.53, p = 0.005). ILD-related hospitalisations were associated with unclassifiable ILD and concomitant emphysema (OR = 2.133, p = 0.001) as well as with other granulomatous ILDs and a positive smoking status (OR = 3.082, p = 0.005). Conclusion: Our results represent a crucial contribution in understanding predisposing factors for hospitalisation in ILD and its major impact on mortality. Further studies to characterize the most vulnerable patient group as well as approaches to prevent hospitalisations are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Diabetes mellitus is associated with increased ex vivo-platelet aggregation and decreased response to aspirin-antithrombotic potential of ACE-inhibitors and AT1-antagonists.
- Author
-
Skowasch, Dirk, Tuleta, Izabela, Viktor, Achim, Bauriedel, Gerhard, and Nickenig, Georg
- Subjects
- *
LETTERS to the editor , *DIABETES - Abstract
A letter to the editor is presented stating that diabetes mellitus is associated with increased ex vivo-platelet aggregation.
- Published
- 2009
- Full Text
- View/download PDF
21. Lung cancer screening with MRI: results of the first screening round.
- Author
-
Meier-Schroers, Michael, Homsi, Rami, Skowasch, Dirk, Buermann, Jens, Zipfel, Matthias, Schild, Hans Heinz, and Thomas, Daniel
- Subjects
- *
EARLY detection of cancer , *LUNG cancer , *CANCER diagnosis , *LUNGS , *THREE-dimensional imaging , *MEDICAL imaging systems , *MAGNETIC resonance imaging - Abstract
Purpose: To evaluate the suitability of MRI for lung cancer screening in a high-risk population. Materials and methods: A 5-year lung cancer screening program comparing MRI and low-dose CT (LDCT) in a high-risk population was initiated. 224 subjects were examined with MRI and LDCT. Acquired MRI sequences were T2w MultiVane XD, balanced steady-state-free precession, 3D T1w GRE, and DWI with a maximum in-room-time of 20 min. Categorization and management of nodules were based on Lung-RADS. MRI findings were correlated with LDCT as a reference. Here, we report on the first screening round. Results: MRI accurately detected 61 of 88 nodules 4-5 mm, 20 of 21 nodules 6-7 mm, 12 of 12 nodules 8-14 mm, 4 of 4 nodules ≥ 15 mm (solid nodules), and 8 of 11 subsolid nodules. Sensitivity/specificity of MRI for nodule detection was 69.3/96.4% for 4-5 mm, 95.2/99.6% for 6-7 mm, 100/99.6% for 8-14 mm, 100/100% for ≥ 15 mm (solid nodules), and 72.7/99.2% for subsolid nodules. The early recall rate was 13.8% for MRI and 12.5% for LDCT. Following Lung-RADS recommendations and based on interdisciplinary consensus, histology was obtained in eight subjects. The biopsy rate was 3.6% for MRI and 3.4% for LDCT. In all of these eight cases, the nodules were carcinomas, and all of them were accurately detected by MRI. Conclusion: The results of the first screening round suggest that MRI is suitable for lung cancer screening with an excellent sensitivity and specificity for nodules ≥ 6 mm. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
22. Pre-Analytical Evaluation of Streck Cell-Free DNA Blood Collection Tubes for Liquid Profiling in Oncology.
- Author
-
Diaz, Inga Medina, Nocon, Annette, Held, Stefanie A. E., Kobilay, Makbule, Skowasch, Dirk, Bronkhorst, Abel J., Ungerer, Vida, Fredebohm, Johannes, Diehl, Frank, Holdenrieder, Stefan, and Holtrup, Frank
- Subjects
- *
CELL-free DNA , *CIRCULATING tumor DNA , *NON-small-cell lung carcinoma , *TUBES , *GENETIC load - Abstract
Excellent pre-analytical stability is an essential precondition for reliable molecular profiling of circulating tumor DNA (ctDNA) in oncological diagnostics. Therefore, in vitro degradation of ctDNA and the additional release of contaminating genomic DNA from lysed blood cells must be prevented. Streck Cell-Free DNA blood collection tubes (cfDNA BCTs) have proposed advantages over standard K2EDTA tubes, but mainly have been tested in healthy individuals. Blood was collected from cancer patients (n = 53) suffering from colorectal (n = 21), pancreatic (n = 11), and non-small-cell lung cancer (n = 21) using cfDNA BCT tubes and K2EDTA tubes that were processed immediately or after 3 days (BCTs) or 6 hours (K2EDTA) at room temperature. The cfDNA isolated from these samples was characterized in terms of yield using LINE-1 qPCR; the level of gDNA contamination; and the mutation status of KRAS, NRAS, and EGFR genes using BEAMing ddPCR. CfDNA yield and gDNA levels were comparable in both tube types and were not affected by prolonged storage of blood samples for at least 3 days in cfDNA BCTs or 6 hours in K2EDTA tubes. In addition, biospecimens collected in K2EDTA tubes and cfDNA BCTs stored for up to 3 days demonstrated highly comparable levels of mutational load across all respective cancer patient cohorts and a wide range of concentrations. Our data support the applicability of clinical oncology specimens collected and stored in cfDNA BCTs for up to 3 days for reliable cfDNA and mutation analyses. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
23. Circulating monocytes and late in-stent restenosis
- Author
-
Bauriedel, Gerhard, Skowasch, Dirk, Jabs, Alexander, Krämer, Stefan, Andrié, René, and Lüderitz, Berndt
- Published
- 2004
- Full Text
- View/download PDF
24. 1121-47 Bone marrow and neural crest derived cells contribute to in-stent restenosis.
- Author
-
Bauriedel, Gerhard, Skowasch, Dirk, Jabs, Alexander, Andrié, René, and Lüderitz, Berndt
- Subjects
- *
NEURAL crest , *BONE marrow , *CORONARY restenosis , *SURGICAL stents , *INFUSION therapy - Published
- 2004
- Full Text
- View/download PDF
25. Antiplatelet effects of angiotensin converting enzyme inhibitors compared with aspirin and clopidogrel: a pilot study using whole blood aggregometry
- Author
-
Skowasch, Dirk, Schneider, Melanie, Andrié, René, Lüderitz, Berndt, and Bauriedel, Gerhard
- Published
- 2002
- Full Text
- View/download PDF
26. Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: A COMPERA analysis.
- Author
-
Rosenkranz, Stephan, Pausch, Christine, Coghlan, John G., Huscher, Doerte, Pittrow, David, Grünig, Ekkehard, Staehler, Gerd, Vizza, Carmine Dario, Gall, Henning, Distler, Oliver, Delcroix, Marion, Ghofrani, Hossain A., Ewert, Ralf, Kabitz, Hans-Joachim, Skowasch, Dirk, Behr, Juergen, Milger, Katrin, Halank, Michael, Wilkens, Heinrike, and Seyfarth, Hans-Jürgen
- Subjects
- *
PULMONARY arterial hypertension , *BRAIN natriuretic factor , *COMORBIDITY , *TREATMENT effectiveness , *OLDER patients , *PULMONARY hypertension - Abstract
A diagnosis of idiopathic pulmonary arterial hypertension (IPAH) is frequently made in elderly patients who present with comorbidities, especially hypertension, coronary heart disease, diabetes mellitus, and obesity. It is unknown to what extent the presence of these comorbidities affects the response to PAH therapies and whether risk stratification predicts outcome in patients with comorbidities. We assessed the database of COMPERA, a European pulmonary hypertension registry, to determine changes after initiation of PAH therapy in WHO functional class (FC), 6-minute walking distance (6MWD), brain natriuretic peptide (BNP) or N-terminal fragment of probrain natriuretic peptide (NT-pro-BNP), and mortality risk assessed by a 4-strata model in patients with IPAH and no comorbidities, 1-2 comorbidities and 3-4 comorbidities. The analysis was based on 1,120 IPAH patients (n = 208 [19%] without comorbidities, n = 641 [57%] with 1-2 comorbidities, and n = 271 [24%] with 3-4 comorbidities). Improvements in FC, 6MWD, BNP/NT-pro-BNP, and mortality risk from baseline to first follow-up were significantly larger in patients with no comorbidities than in patients with comorbidities, while they were not significantly different in patients with 1-2 and 3-4 comorbidities. The 4-strata risk tool predicted survival in patients without comorbidities as well as in patients with 1-2 or 3-4 comorbidities. Our data suggest that patients with IPAH and comorbidities benefit from PAH medication with improvements in FC, 6MWD, BNP/NT-pro-BNP, and mortality risk, albeit to a lesser extent than patients without comorbidities. The 4-strata risk tool predicted outcome in patients with IPAH irrespective of the presence of comorbidities. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
27. Crossover Patient Outcomes for Targeted Lung Denervation in Moderate to Severe Chronic Obstructive Pulmonary Disease: AIRFLOW-2.
- Author
-
Conway, Francesca, Tonkin, James, Valipour, Arschang, Pison, Christophe, Schumann, Christian, Bonta, Peter I., Kessler, Romain, Gesierich, Wolfgang, Darwiche, Kaid, Lamprecht, Bernd, Skowasch, Dirk, Johnson, Philip J., Slebos, Dirk-Jan, and Shah, Pallav L.
- Subjects
- *
LUNG physiology , *INNERVATION of the lungs , *RESEARCH , *PATIENT aftercare , *DENERVATION , *TREATMENT effectiveness , *RANDOMIZED controlled trials , *OBSTRUCTIVE lung diseases , *BLIND experiment , *FORCED expiratory volume , *QUALITY of life , *CROSSOVER trials , *STATISTICAL sampling , *DISEASE exacerbation , *BRONCHOSCOPY - Abstract
Background: Targeted Lung Denervation (TLD) is a potential new therapy for COPD. Radiofrequency energy is bronchoscopically delivered to the airways to disrupt pulmonary parasympathetic nerves, to reduce bronchoconstriction, mucus hypersecretion, and bronchial hyperreactivity. Objectives: This work assesses the effect of TLD on COPD exacerbations (AECOPD) in crossover subjects in the AIRFLOW-2 trial. Method: The AIRFLOW-2 trial is a multicentre, randomized, double-blind, sham-controlled crossover trial of TLD in COPD. Patients with symptomatic COPD on optimal medical therapy with an FEV1 of 30–60% predicted received either TLD or sham bronchoscopy in a 1:1 randomization. Those in the sham arm had the opportunity to cross into the treatment arm after 12 months. The primary end point was rate of respiratory adverse events. Secondary end points included adverse events, changes in lung function and health-related quality of life and symptom scores. Results: Twenty patients were treated with TLD in the crossover phase and were subsequently followed up for 12 months (50% female, mean age 64.1 ± 6.9 years). After TLD, there was a trend towards a reduction in time to first AECOPD (hazard ratio 0.65, p = 0.28, not statistically significant) in comparison to sham follow-up period. There was also a reduction in time to first severe AECOPD in the crossover period (hazard ratio 0.38, p = 0.227, not statistically significant). Symptom scores and lung function showed stability. Conclusions: AIRFLOW-2 crossover data support that of the randomization phase, showing trends towards reduction in COPD exacerbations with TLD. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
28. Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis.
- Author
-
Hoeper, Marius M., Pausch, Christine, Olsson, Karen M., Huscher, Doerte, Pittrow, David, Grünig, Ekkehard, Staehler, Gerd, Vizza, Carmine Dario, Gall, Henning, Distler, Oliver, Opitz, Christian, Gibbs, J. Simon R., Delcroix, Marion, Ghofrani, H. Ardeschir, Ewert, Ralf, Kaemmerer, Harald, Kabitz, Hans-Joachim, Skowasch, Dirk, Behr, Juergen, and Milger, Katrin
- Subjects
- *
PULMONARY arterial hypertension , *PROGNOSIS - Published
- 2022
- Full Text
- View/download PDF
29. Dendritic cells in neointima formation after rat carotid balloon injury: coordinated expression withanti-apoptotic Bcl-2 and HSP47 in arterial repair
- Author
-
Bauriedel, Gerhard, Jabs, Alexander, Skowasch, Dirk, Hutter, Randolph, Badimon, Juan J., Fuster, Valentin, Welsch, Ulrich, Lüderitz, Berndt, and Lüderitz, Berndt
- Subjects
- *
DENDRITIC cells , *B cells , *ENDOTHELIUM , *LYMPHOMAS , *APOPTOSIS - Abstract
: ObjectivesWe sought to evaluate: 1) the contribution of dendritic cells (DCs); and 2) the impact of B-cell lymphoma 2 protein (Bcl-2), a central anti-apoptotic protooncogene, and of heat shock protein 47 (HSP47), indicating subsequent collagen deposition, in neointima formation after angioplasty.: BackgroundThe origin of neointimal cells and the factors that promote their accumulation are still unclear. Previous studies reported intimal presence of DCs and suggested cells of primarily extravascular origin to contribute to arterial repair.: MethodsSprague-Dawley rats underwent carotid balloon angioplasty. At different times after angioplasty, tissue sections were analyzed by immunohistochemistry using OX-62 and S100 as DC markers and antibodies against Bcl-2 and HSP47, supplemented by electron microscopic analysis of cell type and apoptosis.: ResultsFour days after injury, DCs adhered along the internal elastic lamina and demonstrated intense Bcl-2 and HSP47 expression, consistent with low apoptosis. With ongoing neointima enlargement, luminal DCs remained prevalent and were colocalized with Bcl-2 and HSP47, while signaling decreased to basal regions. Media showed no DCs and only low Bcl-2 and HSP47 immunoreactivity. Adventitia transiently revealed a structural separation between day 4 and 7. Whereas the inner layer demonstrated sparse cellularity, apoptosis and no DC, Bcl-2, and HSP47 labeling, the outer layer was characterized by high myofibroblast density with strong Bcl-2 and HSP47 expression but absence of DCs.: ConclusionsWe identify DCs as novel components in early neointima formation, promoted by coordinated anti-apoptotic Bcl-2 and HSP47 expression. Despite intense adventitial remodeling, there is no evidence of adventitial cell transmigration. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
30. Pulmonary Hypertension in Patients With COPD: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).
- Author
-
Vizza, Carmine Dario, Hoeper, Marius M., Huscher, Doerte, Pittrow, David, Benjamin, Nicola, Olsson, Karen M., Ghofrani, H. Ardeschir, Held, Matthias, Klose, Hans, Lange, Tobias, Rosenkranz, Stephan, Dumitrescu, Daniel, Badagliacca, Roberto, Claussen, Martin, Halank, Michael, Vonk-Noordegraaf, Anton, Skowasch, Dirk, Ewert, Ralf, Gibbs, J. Simon R., and Delcroix, Marion
- Subjects
- *
PULMONARY hypertension , *OBSTRUCTIVE lung diseases , *SURVIVAL rate , *PHOSPHODIESTERASE-5 inhibitors , *VASCULAR resistance , *ANTIHYPERTENSIVE agents , *RESEARCH , *RESEARCH methodology , *ACQUISITION of data , *MEDICAL cooperation , *EVALUATION research , *COMPARATIVE studies , *PHOSPHODIESTERASE inhibitors , *LONGITUDINAL method , *DISEASE complications - Abstract
Background: Pulmonary hypertension (PH) in COPD is a poorly investigated clinical condition.Research Question: Which factors determine the outcome of PH in COPD?Study Design and Methods: We analyzed the characteristics and outcome of patients enrolled in the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) with moderate or severe PH in COPD as defined during the 6th PH World Symposium who received medical therapy for PH and compared them with patients with idiopathic pulmonary arterial hypertension (IPAH).Results: The population included incident patients with moderate PH in COPD (n = 68), with severe PH in COPD (n = 307), and with IPAH (n = 489). Patients with PH in COPD were older, predominantly male, and treated mainly with phosphodiesterase-5 inhibitors. Despite similar hemodynamic impairment, patients with PH in COPD achieved a worse 6-min walking distance (6MWD) and showed a more advanced World Health Organization functional class (WHO FC). Transplant-free survival rates at 1, 3, and 5 years were higher in the IPAH group than in the PH in COPD group (IPAH: 94%, 75%, and 55% vs PH in COPD: 86%, 55%, and 38%; P = .004). Risk factors for poor outcomes in PH in COPD were male sex, low 6MWD, and high pulmonary vascular resistance (PVR). In patients with severe PH in COPD, improvements in 6MWD by ≥ 30 m or improvements in WHO FC after initiation of medical therapy were associated with better outcomes.Interpretation: Patients with PH in COPD were functionally more impaired and had a poorer outcome than patients with IPAH. Predictors of death in the PH in COPD group were sex, 6MWD, and PVR. Our data raise the hypothesis that some patients with severe PH in COPD may benefit from PH treatment. Randomized controlled studies are necessary to explore this hypothesis further.Trial Registry: ClinicalTrials.gov; No.: NCT01347216; URL: www.clinicaltrials.gov. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
31. Endobronchial Coil System versus Standard-of-Care Medical Management in the Treatment of Subjects with Severe Emphysema.
- Author
-
Klooster, Karin, Valipour, Arschang, Marquette, Charles-Hugo, Boutros, Jacques, Mal, Hervé, Marceau, Armelle, Shah, Pallav L., Conway, Francesca, Deslée, Gaëtan, Bourdin, Arnaud, Pison, Christophe, Grah, Christian, Hetzel, Martin, Schumann, Christian, Kessler, Romain, Huebner, Ralf-Harto, Skowasch, Dirk, Darwiche, Kaid, Hammerl, Peter, and Stanzel, Franz
- Subjects
- *
RESEARCH , *MEDICAL cooperation , *SEVERITY of illness index , *RANDOMIZED controlled trials , *DESCRIPTIVE statistics , *QUESTIONNAIRES , *LUNG surgery , *STATISTICAL sampling , *PULMONARY emphysema , *BRONCHOSCOPY - Abstract
Background: Bronchoscopic lung volume reduction using endobronchial coils is a new treatment for patients with severe emphysema. To date, the benefits have been modest and have been suggested to be much larger in patients with severe hyperinflation and nonmulti-comorbidity. Objective: We aimed to evaluate the efficacy and safety of endobronchial coil treatment in a randomized multicenter clinical trial using optimized patient selection. Method: Patients with severe emphysema on HRCT scan with severe hyperinflation (residual volume [RV] ≥200% predicted and RV/total lung capacity [TLC] >55%) were randomized to coil treatment or control. Primary outcome measures were differences in the forced expiratory volume in 1 s (FEV1) and St George's Respiratory Questionnaire (SGRQ) total score at 6 months. Results: Due to premature study termination, a total of 120 patients (age 63 ± 7 years, FEV1 29 ± 7% predicted, RV 251 ± 41% predicted, RV/TLC 67 ± 6%, and SGRQ 58 ± 13 points), instead of 210 patients, were randomized. At study termination, 91 patients (57 coil and 34 control) had 6-month results available. Analyses showed significantly greater improvements in favor of the coil group. The increase in FEV1 was greater in the coil group than that in the control group by + 10.3 [+4.7 to +16.0] % and in SGRQ by −10.6 [−15.9 to −5.4] points. At study termination, there were 5 (6.8%) deaths in the coil cohort reported. Conclusion: Despite early study termination, coil treatment compared to control results in a significant improvement in the lung function and quality of life benefits for up to 6 months in patients with emphysema and severe hyperinflation. These improvements were of clinical importance but were associated with a higher likelihood of serious adverse events. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
32. No evidence to support the impact of migration background on treatment response rates and cancer survival: a retrospective matched-pair analysis in Germany.
- Author
-
Rüdiger, Roman, Geiser, Franziska, Ritter, Manuel, Brossart, Peter, Keyver-Paik, Mignon-Denise, Faridi, Andree, Vatter, Hartmut, Bootz, Friedrich, Landsberg, Jennifer, Kalff, Jörg C., Herrlinger, Ulrich, Kristiansen, Glen, Pietsch, Torsten, Aretz, Stefan, Thomas, Daniel, Radbruch, Lukas, Kramer, Franz-Josef, Strassburg, Christian P., Gonzalez-Carmona, Maria, and Skowasch, Dirk
- Abstract
Background: Immigration has taken the central stage in world politics, especially in the developed countries like Germany, where the continuous flow of immigrants has been well documented since 1960s. Strikingly, emerging data suggest that migrant patients have a poorer response to the treatment and lower survival rates in their new host country, raising concerns about health disparities. Herein, we present our investigation on the treatment response rate and cancer survival in German patients with and without an immigrant background that were treated at our comprehensive cancer center in Germany.Methods: Initially, we considered 8162 cancer patients treated at the Center for Integrated Oncology (CIO), University Hospital Bonn, Germany (April 2002-December 2015) for matched-pair analysis. Subsequently, the German patients with a migration background and those from the native German population were manually identified and catalogued using a highly specific name-based algorithm. The clinical parameters such as demographic characteristics, tumor characteristics, defined staging criteria, and primary therapy were further adjusted. Using these stringent criteria, a total of 422 patients (n = 211, Germans with migration background; n = 211, native German population) were screened to compare for the treatment response and survival rates (i.e., 5-year overall survival, progression-free survival, and time to progression).Results: Compared to the cohort with migration background, the cohort without migration background was slightly older (54.9 vs. 57.9 years) while having the same sex distribution (54.5% vs. 55.0% female) and longer follow-up time (36.9 vs. 42.6 months). We did not find significant differences in cancer survival (5-year overall survival, P = 0.771) and the response rates (Overall Remission Rate; McNemar's test, P = 0.346) between both collectives.Conclusion: Contrary to prior reports, we found no significant differences in cancer survival between German patients with immigrant background and native German patients. Nevertheless, the advanced treatment protocols implemented at our comprehensive cancer center may possibly account for the low variance in outcome. To conduct similar studies with a broader perspective, we propose that certain risk factors (country-of-origin-specific infections, dietary habits, epigenetics for chronic diseases etc.) should be considered, specially in the future studies that will recruit new arrivals from the 2015 German refugee crisis. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
33. Higher number of multidisciplinary tumor board meetings per case leads to improved clinical outcome.
- Author
-
Freytag, Marius, Herrlinger, Ulrich, Hauser, Stefan, Bauernfeind, Franz G., Gonzalez-Carmona, Maria A., Landsberg, Jennifer, Buermann, Jens, Vatter, Hartmut, Holderried, Tobias, Send, Thorsten, Schumacher, Martin, Koscielny, Arne, Feldmann, Georg, Heine, Mario, Skowasch, Dirk, Schäfer, Niklas, Funke, Benjamin, Neumann, Michael, and Schmidt-Wolf, Ingo G. H.
- Subjects
- *
PROGRESSION-free survival , *TUMORS , *DISEASE relapse - Abstract
Background: This analysis aims at evaluating the impact of multidisciplinary tumor boards on clinical outcome of multiple tumor entities, the effect of the specific number of multidisciplinary tumor boards and potential differences between the tumor entities.Methods: By a matched-pair analysis we compared the response to treatment, overall survival, relapse or disease free survival and progression free survival of patients whose cases were discussed in a tumor board meeting with patients whose cases were not. It was performed with patients registered in the cancer registry of the University of Bonn and diagnosed between 2010 and 2016. After the matching process with a pool of 7262 patients a total of 454 patients with 66 different tumor types were included in this study.Results: First, patients with three or more multidisciplinary tumor board meetings in their history show a significantly better overall survival than patients with no tumor board meeting. Second, response to treatment, relapse free survival and time to progression were not found to be significantly different. Third, there was no significant difference for a specific tumor entity.Conclusion: This study revealed a positive impact of a higher number of multidisciplinary tumor boards on the clinical outcome. Also, our analysis hints towards a positive effect of multidisciplinary tumor boards on overall survival. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
34. Clinical features of sarcoidosis patients presenting with head and neck manifestations – a two-center retrospective study and proposal of a diagnostic algorithm for the otorhinolaryngologist.
- Author
-
Send, Thorsten, Korsten, Peter, Bertlich, Mattis, Braunwarth, Christoph, Bootz, Friedrich, Skowasch, Dirk, and Jakob, Mark
- Subjects
- *
SARCOIDOSIS diagnosis , *ACADEMIC medical centers , *COMBINATION drug therapy , *DIFFERENTIAL diagnosis , *GLUCOCORTICOIDS , *HEAD , *LUNGS , *LYMPH nodes , *MEDICAL records , *METHOTREXATE , *NECK , *SARCOIDOSIS , *SYMPTOMS , *RETROSPECTIVE studies , *AZATHIOPRINE , *DESCRIPTIVE statistics , *ACQUISITION of data methodology ,THERAPEUTIC use of glucocorticoids - Abstract
Background and Aims: We aimed to investigate the clinical characteristics of patients presenting with sarcoidosis of the head and neck as the initial manifestation and to provide recommendations for the diagnostic work-up for the practicing otorhinolaryngologist. Material and Methods: We performed a retrospective cohort study at two university medical centers in Germany. Patients with a histopathologically confirmed diagnosis of sarcoidosis treated in the otorhinolaryngology departments were analyzed. Results: We identified 62 patients (2003–2016). In total, 85.4% (n = 53) of patients received the initial diagnosis of sarcoidosis during their ENT treatment. Sarcoidosis was detected in the lymph nodes in 42.3% (n = 30) of the patients; 57.7% had extra-lymphatic manifestations. Fifteen patients (24.2%) showed pulmonary involvement. 30.6% (n = 19) were treated with oral glucocorticoids (GC) alone, three patients with GC and methotrexate, one patient initially received a combination of GC and azathioprine, one patient rejected the recommended treatment. Conclusions: Sarcoidosis should be considered as a differential diagnosis in patients presenting with head and neck symptoms. The most frequent presenting symptoms were cervical lymphadenopathy and affection of the paranasal sinuses. Therefore, otorhinolaryngologists should be aware of sarcoidosis and help guide referral strategies as they may be the first physicians treating these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
35. Clinical features of sarcoidosis patients presenting with head and neck manifestations – a two-center retrospective study and proposal of a diagnostic algorithm for the otorhinolaryngologist.
- Author
-
Send, Thorsten, Korsten, Peter, Bertlich3., Mattis, Braunwarth, Christoph, Bootz, Friedrich, Skowasch, Dirk, and Jakob, Mark
- Subjects
- *
SARCOIDOSIS diagnosis , *OTOLARYNGOLOGISTS , *SARCOIDOSIS , *ACADEMIC medical centers , *AZATHIOPRINE , *COMBINATION drug therapy , *LUNGS , *RETROSPECTIVE studies , *LYMPH nodes , *DIFFERENTIAL diagnosis , *HEAD , *METHOTREXATE , *SYMPTOMS , *DESCRIPTIVE statistics , *NECK , *LONGITUDINAL method ,THERAPEUTIC use of glucocorticoids - Abstract
Background and Aims: We aimed to investigate the clinical characteristics of patients presenting with sarcoidosis of the head and neck as the initial manifestation and to provide recommendations for the diagnostic work-up for the practicing otorhinolaryngologist. Material and Methods: We performed a retrospective cohort study at two university medical centers in Germany. Patients with a histopathologically confirmed diagnosis of sarcoidosis treated in the otorhinolaryngology departments were analyzed. Results: We identified 62 patients (2003–2016). In total, 85.4% (n = 53) of patients received the initial diagnosis of sarcoidosis during their ENT treatment. Sarcoidosis was detected in the lymph nodes in 42.3% (n = 30) of the patients; 57.7% had extra-lymphatic manifestations. Fifteen patients (24.2%) showed pulmonary involvement. 30.6% (n = 19) were treated with oral glucocorticoids (GC) alone, three patients with GC and methotrexate, one patient initially received a combination of GC and azathioprine, one patient rejected the recommended treatment. Conclusions: Sarcoidosis should be considered as a differential diagnosis in patients presenting with head and neck symptoms. The most frequent presenting symptoms were cervical lymphadenopathy and affection of the paranasal sinuses. Therefore, otorhinolaryngologists should be aware of sarcoidosis and help guide referral strategies as they may be the first physicians treating these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
36. Clinical Trials with Combination of Cytokine-Induced Killer Cells and Dendritic Cells for Cancer Therapy.
- Author
-
Garofano, Francesca, Gonzalez-Carmona, Maria A., Skowasch, Dirk, Schmidt-Wolf, Roland, Abramian, Alina, Hauser, Stefan, Strassburg, Christian P., and Schmidt-Wolf, Ingo G. H.
- Abstract
Adoptive cellular immunotherapy (ACI) is a promising treatment for a number of cancers. Cytokine-induced killer cells (CIKs) are considered to be major cytotoxic immunologic effector cells. Usually cancer cells are able to suppress antitumor responses by secreting immunosuppressive factors. CIKs have significant antitumor activity and are capable of eradicating tumors with few side effects. They are a very encouraging cell population used against hematological and solid tumors, with an inexpensive expansion protocol which could yield to superior clinical outcome in clinical trials employing adoptive cellular therapy combination. In the last decade, clinical protocols have been modified by enriching lymphocytes with CIK cells. They are a subpopulation of lymphocytes characterized by the expression of CD3+ and CD56+ wich are surface markers common to T lymphocytes and natural killer NK cells. CIK cells are mainly used in two diseases: in hematological patients who suffer relapse after allogeneic transplantation and in patients with hepatic carcinoma after surgical ablation to eliminate residual tumor cells. Dendritic cells DCs could play a pivotal role in enhancing the antitumor efficacy of CIKs. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
37. Obstructive sleep apnea and atherosclerosis—update 2019.
- Author
-
Biener, Leonie, Pizarro, Carmen, Nickenig, Georg, and Skowasch, Dirk
- Subjects
- *
SLEEP apnea syndromes , *CARDIOVASCULAR diseases , *CONTINUOUS positive airway pressure , *HYPERTENSION , *DISEASE risk factors - Abstract
Obstructive sleep apnea (OSA) is a common disorder that has been associated with an increased risk of atherosclerosis and its clinical manifestations. While treatment with continuous positive airway pressure (CPAP) has been shown to exert several beneficial effects on cardiovascular disease and prognosis in observational studies, CPAP was not effective in three recent randomized controlled trials unless it was used for more than 4 hours of sleep. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
38. Pulmonary hypertension due to lung diseases: Updated recommendations from the Cologne Consensus Conference 2018.
- Author
-
Olschewski, Horst, Behr, Jürgen, Bremer, Hinrich, Claussen, Martin, Douschan, Philipp, Halank, Michael, Held, Matthias, Hoeper, Marius M., Holt, Stephan, Klose, Hans, Krüger, Stephan, Lange, Tobias J., Reichenberger, Frank, Skowasch, Dirk, Ulrich, Silvia, Wilkens, Heinrike, and Seeger, Werner
- Abstract
Abstract The 2015 European Guidelines on Pulmonary Hypertension did not only cover pulmonary arterial hypertension (PAH) but also some aspects of pulmonary hypertension (PH) associated with chronic lung disease. The European Guidelines point out that the drugs currently used to treat patients with PAH (prostanoids, endothelin receptor antagonists, phosphodiesterase‑5 inhibitors, sGC stimulators) have not been sufficiently investigated in other forms of PH. Therefore, the European Guidelines do not recommend the use of these drugs in patients with chronic lung disease and PH. This recommendation, however, is not always in agreement with medical ethics as physicians sometimes feel inclined to treat other forms of PH which may affect quality of life and survival of these patients in a similar manner. To this end, it is crucial to consider the severity of both PH and the underlying lung disease. In June 2016, a Consensus Conference organized by the PH working groups of the German Society of Cardiology (DGK), the German Society of Respiratory Medicine (DGP) and the German Society of Paediatric Cardiology (DGPK) was held in Cologne, Germany, to discuss open and controversial issues surrounding the practical implementation of the European Guidelines. Several working groups were created, one of which was dedicated to the diagnosis and treatment of PH in patients with chronic lung disease. The 2018 updated recommendations of this working group are summarized in the present paper. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
39. Impairment of vascular strain in patients with obstructive sleep apnea.
- Author
-
Stumpf, Max Jonathan, Schaefer, Christian Alexander, Krycki, Jan, Schueler, Robert, Pizarro, Carmen, Nickenig, Georg, Steinmetz, Martin, Skowasch, Dirk, and Tuleta, Izabela
- Subjects
- *
SLEEP apnea syndromes , *CARDIOVASCULAR disease treatment , *BODY mass index , *INFLAMMATORY mediators , *ARTERIAL diseases , *BLOOD testing - Abstract
Background: Obstructive sleep apnea (OSA) is an independent risk factor for the development of cardiovascular diseases. Aim of this present study was to evaluate and extend recent research on the influence of obstructive sleep apnea on vascular strain. Methods: A total number of 98 patients were integrated in the study. Patients were grouped according to the Apnea-Hypopnea-Index (AHI) in patients with mild-to-moderate OSA (5/h ≤ AHI < 30/h), severe OSA (AHI ≥ 30/h) and controls (AHI < 5/h). Groups were matched in age, body-mass-index and cardiovascular risks. Vascular strain of common carotid arteries was assessed by ultrasound speckle-tracking. A minor group of 30 patients and controls further underwent assessment of vascular strain of brachial and femoral arteries. Additionally, all patients underwent blood testing to reveal potential influences of inflammatory markers on arterial stiffness. In additional analysis we examined the effect of statin therapy on vascular strain. Results: Patients with OSA showed significantly reduced values of vascular strain of common carotid arteries. Radial and circumferential strains were significantly lower in both patients with mild-to-moderate (p = .05) and patients with severe OSA (p = .001) compared to control. Vascular strain parameters of brachial and femoral arteries showed no consistent results. There were no significant correlations of inflammatory markers with vascular strain parameters. No significant differences in vascular strain were detected between statin and non-statin groups. Conclusion: Patients with OSA show significantly reduced vascular strain assessed by ultrasound-based speckle-tracking. Vascular stiffness increases with the severity of the disease. Target vessels to assess vascular strain in patients with OSA are common carotid arteries, whereas other sites of the arterial tree are not reliable. No significant impact of current statin therapy on vascular strain was found. Further studies are needed to evaluate potential benefit of statins in secondary prevention of atherosclerosis in OSA. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
40. Anxiety and depression in patients three months after myocardial infarction: Association with markers of coagulation and the relevance of age.
- Author
-
Geiser, Franziska, Urbach, Anne Sarah, Harbrecht, Ursula, Conrad, Rupert, Pötzsch, Bernd, Amann, Nele, Kiesewetter, Katharina, Sieke, Alexandra, Wolffs, Kyra, and Skowasch, Dirk
- Subjects
- *
ANXIETY , *MENTAL depression , *FIBRINOLYSIS , *CARDIOVASCULAR diseases risk factors , *PSYCHOLOGICAL distress , *CORONARY disease , *PATIENTS , *MYOCARDIAL infarction complications , *MYOCARDIAL infarction , *AGING , *BLOOD coagulation factors , *PSYCHOLOGICAL tests , *PSYCHOLOGY - Abstract
Objective: Anxiety and depression are associated with an activation of coagulation and an impairment of fibrinolysis, which may contribute to the increased cardiovascular risk associated with the two disorders. However, very few studies have examined the impact of psychological distress on coagulation factors in coronary artery disease patients. The aim of this study was to assess the correlation between anxiety/depression and factors of coagulation and fibrinolysis in patients who had suffered an acute MI three months prior.Methods: In 148 patients, anxiety and depression were assessed by the Hospital Anxiety and Depression Scale (HADS) shortly after MI and three months later. At the second time of assessment, plasma levels of fibrinogen, factor VII, factor VIII, von Willebrand factor, prothrombin-fragment 1 and 2, tissue-plasminogen-activator, plasminogen activator inhibitor-1, D-dimer, and homocysteine were measured.Results: In 32% of the patients, elevated levels of anxiety and depression were found three months after a MI. Multiple regression analyses showed that coagulation and fibrinolysis markers were not significantly associated with HADS anxiety and depression scores. We found that age, gender, BMI, and smoking status were significant predictors for haemostasis factors. A higher age was associated with a higher coagulability but lower anxiety levels.Conclusion: We measured parameters of coagulation and fibrinolysis in patients three months after MI and found no predictive value of HADS anxiety and depression scores shortly after MI or at the time of blood sampling. The effects of age on the relationship between anxiety and haemostasis should be further investigated. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
41. Sleep apnoea is common in severe peripheral arterial disease.
- Author
-
Schahab, Nadjib, Sudan, Sarah, Schaefer, Christian, Tiyerili, Vedat, Steinmetz, Martin, Nickenig, Georg, Skowasch, Dirk, and Pizarro, Carmen
- Subjects
- *
SLEEP apnea syndromes , *ARTERIAL diseases , *ATHEROSCLEROTIC plaque , *REVASCULARIZATION (Surgery) , *TRANSLUMINAL angioplasty - Abstract
Background: Atherosclerotic conditions have been demonstrated to be associated with sleep- disordered breathing (SDB). Peripheral arterial disease (PAD) represents severe atherosclerosis with a high mortality. In early stages of PAD a substantial prevalence of sleep apnoea has already been shown. Here, we sought to determine the frequency of undiagnosed sleep apnoea in a homogeneous group of advanced PAD patients undergoing percutaneous revascularization. Methods: 59 consecutive patients (mean age: 71.1 ± 9.8 years, 67.8% males) with PAD in Fontaine stages IIb-IV that underwent percutaneous transluminal angioplasty at our department were enrolled for pre-procedural polygraphy. Results: Patients appertained to Fontaine clinical stage IIb, III and IV in 54.2%, 23.8% and 22.% of cases, respectively, and were principally intervened for femoropopliteal occlusive disease (71.2% of total study population). Polygraphy revealed sleep apnoea in 48 out of 59 patients (81.4%), of whom 60.4% offered a primarily obstructive-driven genesis. Among those patients with polygraphically confirmed sleep apnoea, mean apnoea hypopnoea index (AHI) and mean oxygen desaturation index (ODI) averaged 28.2 ± 19.5/h and 26.7 ± 18.8/h, respectively. 18 patients even offered an AHI ≥30/h that is indicative of severe sleep apnoea. For obstructive-driven apnoeic events, AHI correlated significantly with PAD severity stages (p = 0.042). Conclusions: In our PAD collective, sleep apnoea was frequent and obstructive sleep apnoea´s severity correlated with PAD severity stages. Long-term results regarding the vasoprotective impact of CPAP treatment on PAD course remains to be determined. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
42. Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry.
- Author
-
Kreuter, Michael, Swigris, Jeff, Pittrow, David, Geier, Silke, Klotsche, Jens, Prasse, Antje, Wirtz, Hubert, Koschel, Dirk, Andreas, Stefan, Claussen, Martin, Grohé, Christian, Wilkens, Henrike, Hagmeyer, Lars, Skowasch, Dirk, Meyer, Joachim F., Kirschner, Joachim, Gläser, Sven, Herth, Felix J. F., Welte, Tobias, and Neurohr, Claus
- Subjects
- *
IDIOPATHIC pulmonary fibrosis , *HEALTH status indicators , *WELL-being , *HEALTH behavior , *EVERYDAY life , *HOSPITAL care , *LONGITUDINAL method , *LUNGS , *MULTIVARIATE analysis , *PSYCHOMETRICS , *QUALITY of life , *QUESTIONNAIRES , *RESPIRATORY measurements , *SPIROMETRY , *TIME , *COMORBIDITY , *ACQUISITION of data , *VITAL capacity (Respiration) , *SEVERITY of illness index , *DIAGNOSIS - Abstract
Background: The INSIGHTS-IPF registry provides one of the largest data sets of clinical data and self-reported patient related outcomes including health related quality of life (QoL) on patients with idiopathic pulmonary fibrosis (IPF). We aimed to describe associations of various QoL instruments between each other and with patient characteristics at baseline.Methods: Six hundred twenty-three IPF patients with available QoL data (St George's Respiratory Questionnaire SGRQ, UCSD Shortness-of-Breath Questionnaire SoB, EuroQol visual analogue scale and index EQ-5D, Well-being Index WHO-5) were analysed. Mean age was 69.6 ± 8.7 years, 77% were males, mean disease duration 2.0 ± 3.3 years, FVC pred was 67.5 ± 17.8%, DLCO pred 35.6 ± 17%.Results: Mean points were SGRQ total 48.3, UCSD SoB 47.8, EQ-5D VAS 66.8, and WHO-5 13.9. These instruments had a high or very high correlation (exception WHO-5 to EQ-5D VAS with moderate correlation). On bivariate analysis, QoL by SGRQ total was statistically significantly associated with clinical symptoms (NYHA; p < 0.001), number of comorbidities (p < 0.05), hospitalisation rate (p < 0.01) and disease severity (as measured by GAP score, CPI, FVC and 6-min walk test; p < 0.05 each). Multivariate analyses showed a significant association between QoL (by SGRQ total) and IPF duration, FVC, age, NYHA class and indication for long-term oxygen treatment.Conclusions: Overall, IPF patients under real-life conditions have lower QoL compared to those in clinical studies. There is a meaningful relationship between QoL and various patient characteristics.Trial Registration: The INSIGHTS-IPF registry is registered at Clinicaltrials.gov ( NCT01695408 ). [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
43. Pseudoxanthoma Elasticum – Also a Lung Disease? The Respiratory Affection of Patients with Pseudoxanthoma Elasticum.
- Author
-
Pingel, Simon, Passon, Sebastian Gorgonius, Pausewang, Kristin Solveig, Blatzheim, Anna Katharina, Pizarro, Carmen, Tuleta, Izabela, Gliem, Martin, Charbel Issa, Peter, Schahab, Nadjib, Nickenig, Georg, Skowasch, Dirk, and Schaefer, Christian Alexander
- Subjects
- *
PSEUDOXANTHOMA elasticum , *LUNG disease diagnosis , *LUNG diseases , *PULMONARY function tests , *GENETIC mutation , *PLETHYSMOGRAPHY , *PATIENTS - Abstract
Background: Pseudoxanthoma elasticum (PXE) is an autosomal-recessive mineralisation disorder caused by loss of function mutations in the ABCC6 Gen. Histological findings and data of an autopsy of a PXE-patient suggest a possible pulmonal calcification. So far, there exists no clinical data whether PXE patients actually are at high risk of developing pulmonary disorder. Methods: In a cross-sectional study, 35 PXE patients and 15 healthy controls underwent a pulmonary function testing, including spirometry, body plethysmography and carbon monoxide diffusing test. Additionally, PXE patients completed a COPD–Assessment-Test (CAT). Results: We observed in PXE patients normal values for predicted vital capacity (VC%; 96.0±13.0%), predicted total lung capacity (TLC%; 98.2±12.0%) and predicted forced expiration volume (FEV1%; 102.5±15.6%), whereas compared to healthy controls the PXE group showed significant diminished values for carbon monoxide diffusing capacity (DLCO, 7.2 ±1.4mmol/min/kPa vs. 8.6 ±1.5 mmol/min/kPa; p = 0.008) and predicted carbon monoxide diffusing capacity (DLCO%; 79.7±11.5% vs. 87.2±6.6%; p = 0.008). 11/35 (31.4%) PXE patients showed pathological DLCO% values under 75% (68.5%±5.4%). Conclusion: PXE patients demonstrated a regular lung function testing, but nevertheless they had impaired CO diffusing parameters, which might be associated with a preclinical state of an interstitial lung disease and a risk for restrictive ventilation disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
44. Impact of macitentan on right ventricular myocardial function in pulmonary arterial hypertension.
- Author
-
Pizarro, Carmen, Meyer zur Heide genannt Meyer-Arend, Julia, Schueler, Robert, Hammerstingl, Christoph, Tuleta, Izabela, Nickenig, Georg, and Skowasch, Dirk
- Subjects
- *
ENDOTHELIN receptors , *PULMONARY hypertension treatment , *PULMONARY hypertension , *MORTALITY , *ECHOCARDIOGRAPHY , *DISEASE progression , *PATIENTS - Published
- 2016
- Full Text
- View/download PDF
45. Recurrent Chronic Obstructive Pulmonary Disease Exacerbations after Endobronchial Valve Implantation Are Associated with the Presence of Pseudomonas aeruginosa.
- Author
-
Tuleta, Izabela, Pizarro, Carmen, Molitor, Ernst, Kristiansen, Glen, Nickenig, Georg, and Skowasch, Dirk
- Subjects
- *
PULMONARY emphysema , *LONGITUDINAL method , *OBSTRUCTIVE lung diseases , *PSEUDOMONAS , *TRACHEA , *DISEASE relapse , *DISEASE exacerbation , *MEDICAL device removal , *BACTERIAL contamination - Abstract
Background: Endoscopic lung volume reduction by means of endobronchial valve implantation is an established therapy in patients with severe emphysema. However, longterm complications such as chronic obstructive pulmonary disease (COPD) exacerbations are a limitation of this method. Objectives: As the mechanisms underlying increased rates of COPD exacerbations are unknown, the aim of our study was to determine whether infectious or inflammatory factors may contribute to these events and to investingate the consequent need for valve explantation. Methods: Tissue surrounding explanted endobronchial Zephyr valves was examined by microbiological, histological and cytological methods. Additionally, we performed a microbiological analysis of tracheal aspirates before both valve implantation and valve explantation. Moreover, blood samples were collected for the analysis of inflammatory markers. Results: Endobronchial valves were explanted from 16 patients. Reasons for explantation were frequent postprocedural COPD exacerbations (group 1: 8 patients) or loss of clinical benefit (group 2: 8 patients). Compared to group 2, the microbiological examinations of valve lavage and tracheal aspirates from patients in group 1 showed a higher detection of Gramnegative bacteria. In particular, infection with Pseudomonas aeruginosa was more predominant in group 1, while no presence could be detected in group 2. Blood inflammatory markers tended to be slightly higher in group 1 than in group 2; however, without reaching statistical significance. Conclusions: Increased rates of COPD exacerbations after endobronchial valve implantation are associated with the presence of P. aeruginosa. The finding warrants further investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
46. MRI of the lung using the PROPELLER technique: Artifact reduction, better image quality and improved nodule detection.
- Author
-
Meier-Schroers, Michael, Kukuk, Guido, Homsi, Rami, Skowasch, Dirk, Schild, Hans Heinz, and Thomas, Daniel
- Subjects
- *
LUNGS , *AXIAL flow pumps , *MEDICAL artifacts , *IMAGE quality analysis , *LUNG cancer diagnosis , *RADIATION doses , *MAGNETIC resonance imaging - Abstract
Purpose: To evaluate the benefit of the PROPELLER technique (Periodically Rotated Overlapping ParallEL Lines with Enhanced Reconstruction, MultiVane, MV) for MR imaging of the lung.Materials and Methods: 30 Participants of a lung cancer screening program were recruited for the comparison of T2-MV and T2-Fast Spin Echo (FSE) sequences at 1.5T. Two readers evaluated artifacts, image quality, and pulmonary lesions. Artifacts and image quality were rated using a four-point scale. Lesion detection was correlated to low-dose computed tomography (CT). Wilcoxon rank-test for ratings of artifacts and image quality, sensitivity and specificity values for lesion detection, and Cohen's kappa for inter-rater agreement were used.Results: The MV sequence showed less pulsation and motion artifacts, and higher image quality (p=0.001 for R1, p=0.002 for R2) than FSE (p<0.001 for both readers, R1 and R2). Inter-rater agreement was excellent for lesion detection (0.84-0.95) and good to excellent for artifacts and image quality (0.66-0.84). 17 patients had lesions <8mm, and 7 had lesions >8mm as seen on CT. For R1 and R2, the MV sequence allowed for higher detection rates of pulmonary lesions <8mm with a sensitivity of 56% (R1) and 59% (R2); the FSE sequence achieved 50% (R1) and 53% (R2). Specificity was also higher for MV with 94% (R1) and 83% (R2) compared to 78% (R1) and 76% (R2). Lesions >8mm were detected with a sensitivity of 100% by both readers on both MV and FSE images. For both readers, specificity for larger lesions was higher on MV images with 100% compared to 96%.Conclusion: The superior image quality and the very robust artifact reduction make MV a promising technique for MRI of the lung compared to FSE, especially since it is not requiring breathholds. Moreover, MV allows for improved lesion detection. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
47. Prevalence and Impact of Sleep Disordered Breathing in Patients with Severe Aortic Stenosis.
- Author
-
Linhart, Markus, Sinning, Jan-Malte, Ghanem, Alexander, Kozhuppakalam, Finny J., Fistéra, Rebecca, Hammerstingl, Christoph, Pizarro, Carmen, Grube, Eberhard, Werner, Nikos, Nickenig, Georg, and Skowasch, Dirk
- Subjects
- *
SLEEP disorder diagnosis , *SLEEP disorders , *RESPIRATION , *AORTIC stenosis , *AORTIC valve transplantation , *DISEASE prevalence , *PATIENTS - Abstract
Background: Unlike the well-established association between sleep disordered breathing (SDB) and chronic heart failure, the relationship between SDB and severe aortic stenosis (AS) is not well investigated. Given the increasing prevalence of AS, and the improving prognosis of high risk AS patients attributable to transcatheter aortic valve implantation (TAVI), the prevalence and impact of SDB needs to be better understood. Methods and Results: In this study, 140 patients with severe AS underwent polygraphy prior to TAVI. Clinical and hemodynamic parameters were recorded. Patients were followed for 573±405 days. We found that 99/140 patients (71%) had SDB with a mean apnoea-hypopnoea-index of 24±17/h. SDB was mild in 27%, moderate in 23% and severe in 21% of patients. In addition, 35 patients (25%) had obstructive sleep apnoea (OSA), whereas 64 patients (46%) had central sleep apnoea (CSA). Patients with OSA had predominantly mild SDB (20/38 pts.), and patients with CSA mostly had severe SDB (24/29 pts.). The prevalence and distribution of OSA and CSA were independent of left ventricular function. Overall, 1 and 2 year survival rates (74% and 71%, resp.) did not differ significantly between patients without SDB or those with OSA and CSA (p=0.81). Conclusions: SDB, with a preponderance of CSA, was found to be highly prevalent in patients with high-grade AS scheduled for TAVI. SDB prevalence was independent of left ventricular function. Mortality after TAVI was not influenced by the type or severity of SDB. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
48. Impact of Endoscopic Lung Volume Reduction on Right Ventricular Myocardial Function.
- Author
-
Pizarro, Carmen, Schueler, Robert, Hammerstingl, Christoph, Tuleta, Izabela, Nickenig, Georg, and Skowasch, Dirk
- Subjects
- *
RIGHT heart ventricle , *LUNG volume measurements , *ENDOSCOPIC surgery , *PULMONARY emphysema , *BRONCHOSCOPY , *ECHOCARDIOGRAPHY - Abstract
Introduction: Endoscopic lung volume reduction (ELVR) provides a minimally invasive therapy for patients with severe lung emphysema. As its impact on right ventricular (RtV) function is undefined, we examined the extent of RtV functional changes following ELVR, as assessed by use of speckle tracking-based RtV deformation analysis. Methods: We enrolled 32 patients with severe emphysematous COPD scheduled for bronchoscopic LVR using endobronchial valves (Zephyr, PulmonX, Inc.), comprising 16 matched clinical responders and 16 non-responders. Echocardiography was conducted one day prior to ELVR and at an eight-week postprocedural interval. Results: Patients were predominantly of late middle-age (65.8±8.7yrs), male (62.5%) and presented advanced COPD emphysema (means FEV1 and RV: 32.6% and 239.1% of predicted, respectively). After ELVR, RtV apical longitudinal strain improved significantly in the total study cohort (-7.96±7.02% vs. -13.35±11.48%, p=0.04), whereas there were no significant changes in other parameters of RtV function such as RtV global longitudinal strain, TAPSE or pulmonary arterial systolic pressure. In responding patients, 6MWT-improvement correlated with a decrease in NT-proBNP (Pearson´s r: -0.53, p=0.03). However, clinical non-responders did not exhibit any RtV functional improvement. Discussion: ELVR beneficially impacts RtV functional parameters. Speckle tracking-based RtV apical longitudinal strain analysis allows early determination of RtV contractile gain and identification of clinical responsiveness. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
49. Underdiagnosis of Obstructive Sleep Apnoea in Peripheral Arterial Disease.
- Author
-
Pizarro, Carmen, Schaefer, Christian, Kimeu, Irene, Pingel, Simon, Horlbeck, Fritz, Tuleta, Izabela, Nickenig, Georg, and Skowasch, Dirk
- Subjects
- *
PERIPHERAL vascular disease treatment , *ACADEMIC medical centers , *ACTIVE oxygen in the body , *CARDIOVASCULAR diseases risk factors , *CHI-squared test , *DIAGNOSIS , *EPIDEMIOLOGICAL research , *GAIT in humans , *LEG , *LIFE skills , *LONGITUDINAL method , *PERIPHERAL vascular diseases , *PHYSICAL diagnosis , *PROBABILITY theory , *QUESTIONNAIRES , *SLEEP apnea syndromes , *SMOKING , *STATISTICAL hypothesis testing , *STATISTICS , *T-test (Statistics) , *COMORBIDITY , *POLYSOMNOGRAPHY , *DATA analysis , *BODY mass index , *RETROSPECTIVE studies , *SEVERITY of illness index , *ANKLE brachial index , *DATA analysis software , *DESCRIPTIVE statistics , *KRUSKAL-Wallis Test , *DISEASE complications , *DISEASE risk factors ,PERIPHERAL vascular disease diagnosis - Abstract
Background: Obstructive sleep apnoea (OSA) has interdependently been related to the onset and progression of a large portion of atherosclerotic cardiovascular disorders. In due consideration of OSA-mediated endothelial dysfunction, its impact on peripheral artery disease is conceivable, but undefined. Objectives: The aim of this study was to identify the prevalence of OSA in a lower extremity artery disease (LEAD) study population. Methods: A total of 91 patients receiving in- and outpatient treatment for LEAD were included in this prospectively conducted trial. In addition to an angiological examination, all patients underwent nocturnal screening for sleep-disordered breathing by use of SOMNOcheck micro® (SC micro) and - depending on the results obtained - polysomnography. Results: Patients were principally late middle-aged (69.3 ± 10.8 years), male (71.4%) and slightly overweight (BMI 26.8 ± 3.9). Overnight screening determined a sleep apnoea prevalence of 78.0%, of which 90.1% exhibited a predominantly obstructive genesis. The mean apnoea-hypopnoea index (AHI; events/h) and oxygen desaturation index (events/h) averaged 11.8 ± 13.4 and 8.9 ± 14.2, respectively. The individual AHI categories of non-pathological (<5), mild (5 to <15), moderate (15 to <30) and severe sleep apnoea (≥30) accounted for 22.0, 59.3, 13.2 and 5.5%, respectively. A distributive examination of AHI within LEAD severity groups evinced a significant association (p = 0.047). In cases of at least moderate sleep apnoea (AHI ≥15) polysomnography was performed (n = 17, 18.7% of the whole collective). Correlative analysis revealed a significant correlation between values obtained by SC micro recording and polysomnography, establishing the diagnostic accuracy of the screening results. Conclusions: OSA exhibits an important prevalence of 70.3% in LEAD patients with prior undiagnosed sleep-disordered breathing, indicating major OSA unawareness in this cardiovascular cohort. However, the impact of OSA treatment on LEAD propagation remains to be determined. © 2015 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
50. Effect of Endobronchial Valve Therapy on Pulmonary Perfusion and Ventilation Distribution.
- Author
-
Pizarro, Carmen, Ahmadzadehfar, Hojjat, Essler, Markus, Tuleta, Izabela, Fimmers, Rolf, Nickenig, Georg, and Skowasch, Dirk
- Subjects
- *
HEART valves , *OBSTRUCTIVE lung diseases , *LUNG radiography , *RADIONUCLIDE imaging , *VENTILATION - Abstract
Introduction: Endoscopic lung volume reduction (ELVR) is an emerging therapy for emphysematous COPD. However, any resulting changes in lung perfusion and ventilation remain undetermined. Here, we report ELVR-mediated adaptations in lung perfusion and ventilation, as investigated by means of pulmonary scintigraphy. Methods: In this observational study, we enrolled 26 patients (64.9±9.4 yrs, 57.7% male) with COPD heterogeneous emphysema undergoing ELVR with endobronchial valves (Zephyr, Pulmonx, Inc.). Mean baseline FEV1 and RV were 32.9% and 253.8% predicted, respectively. Lung scintigraphy was conducted prior to ELVR and eight weeks thereafter. Analyses of perfusion and ventilation shifts were performed and complemented by correlation analyses between paired zones. Results: After ELVR, target zone perfusion showed a mean relative reduction of 43.32% (p<0.001), which was associated with a significant decrease in target zone ventilation (p<0.001). Perfusion of the contralateral untreated zone and of the contralateral total lung exhibited significant increases post-ELVR (p = 0.002 and p = 0.005, respectively); both correlated significantly with the corresponding target zone perfusion adaptations. Likewise, changes in target zone ventilation correlated significantly with ventilatory changes in the contralateral untreated zone and the total contralateral lung (Pearson’s r: −0.42, p = 0.04 and Pearson’s r: −0.42, p = 0.03, respectively). These effects were observed in case of clinical responsiveness to ELVR, as assessed by changes in the six-minute walk test distance. Discussion: ELVR induces a relevant decrease in perfusion and ventilation of the treated zone with compensatory perfusional and ventilatory redistribution to the contralateral lung, primarily to the non-concordant, contralateral zone. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.